Last reviewed · How we verify
NCT05808803
Aberrant Myeloid Lineage Differentiation in HIV/AIDS Patients
trial in HIV Infections in 782 participants. Completed in 31 January 2022.
31 October 2020
Quick facts
| Lead sponsor | Zhongnan Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 782 |
| Start date | 1 January 2016 |
| Primary completion | 31 October 2020 |
| Estimated completion | 31 January 2022 |
Conditions studied
- HIV Infections — all drugs for HIV Infections →
- Leukemia — all drugs for Leukemia →
Sponsor
Zhongnan Hospital
Who can join
Eligibility, any sex, with HIV Infections or Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators included 782 HIV-infected patients from January 2016 to October 2020 Zhongnan Hospital of Wuhan University, whose AIDS diagnosis criteria met the "AIDS Diagnosis and Treatment Guide (2018 edition)" of Chinese Medical Association.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Associated factors and prognostic implications of neutropenia in individuals with HIV/AIDS.
Li P, Lv X, Shen H, Fang J, et al · · 2025 · cited 2× · PMID 39789626 · DOI 10.1186/s12985-025-02624-x
Verify or expand the search:
- PubMed search for NCT05808803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV Infections
Currently open trials in the same condition.
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
- NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
- NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
- NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting
Other Zhongnan Hospital trials
Trials by the same sponsor.
- NCT07515963 — FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. · Phase 2 · not yet recruiting
- NCT07420036 — An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, · EARLY_PHASE1 · not yet recruiting
- NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
- NCT07363330 — A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07460258 — A Study on the Effect of Medical Students' Literature Reading Patterns on Cognitive Load and Academic Writing Ability · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05808803 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongnan Hospital
- Last refreshed: 28 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05808803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing